Plasma cortisol level in amyotrophic lateral sclerosis

Rossella Spataro, Paolo Volanti, Francesco Vitale, Francesco Meli, Tiziana Colletti, Antonino Di Natale, Vincenzo La Bella

Research output: Contribution to journalArticle

Abstract

Background. Amyotrophic Lateral sclerosis (ALS) is associatedwith a significant distress, being linked to changes in hypothalamic-pituitary-adrenal axis activity. A loss of cortisol circadian rhythmicity in ALS patients was suggested, while more recently an increased plasma cortisol level in the disease has been reported. Objective. To assay the circadian plasma cortisol level in ALS and to study its relationship with the clinical phenotype and the rate of disease progression. Patients andmethods. 135 ALS patients (Bulbar, 33; Spinal, 102;M/F=1.73) and 110 controls (not affected by neurological or psychiatric disorders, free of drugs; M/F=1.75) were recruited. Disease progression was scored with FS.Morning and evening plasma cortisol levels (μg/dl)were assayed fromfasting ALS patients and controls using Elecsys® Cortisol Immunoassay System. Results.We found that themorning level of cortisol in ALS patientswas higher than controls (morning: ALS, 15.2 [11.5-18.9] vs Controls, 11.4 [8.8-14.3], p b 0.001; evening: ALS, 7.5[4.7-11.8] vs Controls, 7.9[5.4-10.0], p=0.6). Furthermore, the hormone's level was higher in the spinal-onset group (Spinal, 15.9[11.9-19.0] vs Bulbar, 13.5[10.1-18.6] vs controls, 11.4[8.8-14.3], p b 0.001) and in patients with intermediate/rapid disease course. Conclusions.Morning plasma cortisol level is increased in ALS, mainly in spinal-onset patients and in those with intermediate/rapidly progressing disease. The plasmatic changes of the steroid hormone appear however too small to make it a sensitive biochemical marker in this severe neurodegenerative disease.

Original languageEnglish
Pages (from-to)282-286
Number of pages5
JournalJournal of the Neurological Sciences
Volume358
Issue number1-2
DOIs
Publication statusPublished - Feb 14 2015

Fingerprint

Amyotrophic Lateral Sclerosis
Hydrocortisone
Disease Progression
Hormones
Periodicity
Immunoassay
Neurodegenerative Diseases
Psychiatry
Biomarkers
Steroids
Phenotype

Keywords

  • ALS
  • ALSFRS-R
  • Biomarker
  • Cortisol
  • Disease progression

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Spataro, R., Volanti, P., Vitale, F., Meli, F., Colletti, T., Di Natale, A., & La Bella, V. (2015). Plasma cortisol level in amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 358(1-2), 282-286. https://doi.org/10.1016/j.jns.2015.09.011

Plasma cortisol level in amyotrophic lateral sclerosis. / Spataro, Rossella; Volanti, Paolo; Vitale, Francesco; Meli, Francesco; Colletti, Tiziana; Di Natale, Antonino; La Bella, Vincenzo.

In: Journal of the Neurological Sciences, Vol. 358, No. 1-2, 14.02.2015, p. 282-286.

Research output: Contribution to journalArticle

Spataro, R, Volanti, P, Vitale, F, Meli, F, Colletti, T, Di Natale, A & La Bella, V 2015, 'Plasma cortisol level in amyotrophic lateral sclerosis', Journal of the Neurological Sciences, vol. 358, no. 1-2, pp. 282-286. https://doi.org/10.1016/j.jns.2015.09.011
Spataro R, Volanti P, Vitale F, Meli F, Colletti T, Di Natale A et al. Plasma cortisol level in amyotrophic lateral sclerosis. Journal of the Neurological Sciences. 2015 Feb 14;358(1-2):282-286. https://doi.org/10.1016/j.jns.2015.09.011
Spataro, Rossella ; Volanti, Paolo ; Vitale, Francesco ; Meli, Francesco ; Colletti, Tiziana ; Di Natale, Antonino ; La Bella, Vincenzo. / Plasma cortisol level in amyotrophic lateral sclerosis. In: Journal of the Neurological Sciences. 2015 ; Vol. 358, No. 1-2. pp. 282-286.
@article{3ff7a561531342ecac433bb4ed3cfeeb,
title = "Plasma cortisol level in amyotrophic lateral sclerosis",
abstract = "Background. Amyotrophic Lateral sclerosis (ALS) is associatedwith a significant distress, being linked to changes in hypothalamic-pituitary-adrenal axis activity. A loss of cortisol circadian rhythmicity in ALS patients was suggested, while more recently an increased plasma cortisol level in the disease has been reported. Objective. To assay the circadian plasma cortisol level in ALS and to study its relationship with the clinical phenotype and the rate of disease progression. Patients andmethods. 135 ALS patients (Bulbar, 33; Spinal, 102;M/F=1.73) and 110 controls (not affected by neurological or psychiatric disorders, free of drugs; M/F=1.75) were recruited. Disease progression was scored with FS.Morning and evening plasma cortisol levels (μg/dl)were assayed fromfasting ALS patients and controls using Elecsys{\circledR} Cortisol Immunoassay System. Results.We found that themorning level of cortisol in ALS patientswas higher than controls (morning: ALS, 15.2 [11.5-18.9] vs Controls, 11.4 [8.8-14.3], p b 0.001; evening: ALS, 7.5[4.7-11.8] vs Controls, 7.9[5.4-10.0], p=0.6). Furthermore, the hormone's level was higher in the spinal-onset group (Spinal, 15.9[11.9-19.0] vs Bulbar, 13.5[10.1-18.6] vs controls, 11.4[8.8-14.3], p b 0.001) and in patients with intermediate/rapid disease course. Conclusions.Morning plasma cortisol level is increased in ALS, mainly in spinal-onset patients and in those with intermediate/rapidly progressing disease. The plasmatic changes of the steroid hormone appear however too small to make it a sensitive biochemical marker in this severe neurodegenerative disease.",
keywords = "ALS, ALSFRS-R, Biomarker, Cortisol, Disease progression",
author = "Rossella Spataro and Paolo Volanti and Francesco Vitale and Francesco Meli and Tiziana Colletti and {Di Natale}, Antonino and {La Bella}, Vincenzo",
year = "2015",
month = "2",
day = "14",
doi = "10.1016/j.jns.2015.09.011",
language = "English",
volume = "358",
pages = "282--286",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Plasma cortisol level in amyotrophic lateral sclerosis

AU - Spataro, Rossella

AU - Volanti, Paolo

AU - Vitale, Francesco

AU - Meli, Francesco

AU - Colletti, Tiziana

AU - Di Natale, Antonino

AU - La Bella, Vincenzo

PY - 2015/2/14

Y1 - 2015/2/14

N2 - Background. Amyotrophic Lateral sclerosis (ALS) is associatedwith a significant distress, being linked to changes in hypothalamic-pituitary-adrenal axis activity. A loss of cortisol circadian rhythmicity in ALS patients was suggested, while more recently an increased plasma cortisol level in the disease has been reported. Objective. To assay the circadian plasma cortisol level in ALS and to study its relationship with the clinical phenotype and the rate of disease progression. Patients andmethods. 135 ALS patients (Bulbar, 33; Spinal, 102;M/F=1.73) and 110 controls (not affected by neurological or psychiatric disorders, free of drugs; M/F=1.75) were recruited. Disease progression was scored with FS.Morning and evening plasma cortisol levels (μg/dl)were assayed fromfasting ALS patients and controls using Elecsys® Cortisol Immunoassay System. Results.We found that themorning level of cortisol in ALS patientswas higher than controls (morning: ALS, 15.2 [11.5-18.9] vs Controls, 11.4 [8.8-14.3], p b 0.001; evening: ALS, 7.5[4.7-11.8] vs Controls, 7.9[5.4-10.0], p=0.6). Furthermore, the hormone's level was higher in the spinal-onset group (Spinal, 15.9[11.9-19.0] vs Bulbar, 13.5[10.1-18.6] vs controls, 11.4[8.8-14.3], p b 0.001) and in patients with intermediate/rapid disease course. Conclusions.Morning plasma cortisol level is increased in ALS, mainly in spinal-onset patients and in those with intermediate/rapidly progressing disease. The plasmatic changes of the steroid hormone appear however too small to make it a sensitive biochemical marker in this severe neurodegenerative disease.

AB - Background. Amyotrophic Lateral sclerosis (ALS) is associatedwith a significant distress, being linked to changes in hypothalamic-pituitary-adrenal axis activity. A loss of cortisol circadian rhythmicity in ALS patients was suggested, while more recently an increased plasma cortisol level in the disease has been reported. Objective. To assay the circadian plasma cortisol level in ALS and to study its relationship with the clinical phenotype and the rate of disease progression. Patients andmethods. 135 ALS patients (Bulbar, 33; Spinal, 102;M/F=1.73) and 110 controls (not affected by neurological or psychiatric disorders, free of drugs; M/F=1.75) were recruited. Disease progression was scored with FS.Morning and evening plasma cortisol levels (μg/dl)were assayed fromfasting ALS patients and controls using Elecsys® Cortisol Immunoassay System. Results.We found that themorning level of cortisol in ALS patientswas higher than controls (morning: ALS, 15.2 [11.5-18.9] vs Controls, 11.4 [8.8-14.3], p b 0.001; evening: ALS, 7.5[4.7-11.8] vs Controls, 7.9[5.4-10.0], p=0.6). Furthermore, the hormone's level was higher in the spinal-onset group (Spinal, 15.9[11.9-19.0] vs Bulbar, 13.5[10.1-18.6] vs controls, 11.4[8.8-14.3], p b 0.001) and in patients with intermediate/rapid disease course. Conclusions.Morning plasma cortisol level is increased in ALS, mainly in spinal-onset patients and in those with intermediate/rapidly progressing disease. The plasmatic changes of the steroid hormone appear however too small to make it a sensitive biochemical marker in this severe neurodegenerative disease.

KW - ALS

KW - ALSFRS-R

KW - Biomarker

KW - Cortisol

KW - Disease progression

UR - http://www.scopus.com/inward/record.url?scp=84956721606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956721606&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2015.09.011

DO - 10.1016/j.jns.2015.09.011

M3 - Article

C2 - 26384616

AN - SCOPUS:84956721606

VL - 358

SP - 282

EP - 286

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

IS - 1-2

ER -